Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger
will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.


Carolinas HealthCare System

Research and Clinical Trials

Title  
A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg
Brief Description  
This research study is to determine the effectiveness and safety of a new "investigational" product called LiRIS® 400 mg. The investigational product (IP) is pretzel shaped. It is made of medical grade silicone and contains a wire to maintain the pretzel shape in the bladder and will be compared with a placebo that is of the same construction but does not contain any drug. The IP will be placed in the bladder for 28 days. The study will consist of a screening period.
Who may be Eligible  
Inclusion: Female greater than 18 years of age with a diagnosis of IC with Hunner's Lesions; Mean daily average of pain between 4 and 9.5 on 0-10 NRS pain score; Daily average micturition frequency greater than 8 episodes. Exclusion: Patient who is pregnant, nursing or planning a pregnancy or unwilling to use reliable contraception/abstinence during the study; Cytoscopy within 4 weeks of the screening period. History of cardiovascular conditions including cardiac arrest, clinically significant arrhythmia or bradycardia; Evidence of urethral obstruction or stricture; Current pelvic pain of extravesicle originl; Initiation of physical therapy within 4 weeks prior to screening; Current or planned use of electrostimulation/neuromodulation device; History of any other diagnosis that may account for the symptoms of IC; More than 3 urogenital bacteria or viral infections in the last 12 months; Treatment with botulinum toxin therapy within 9 months of screening; Participation in a clinical study or treatment with IP within 4 weeks prior to screening; Previous exposure to LiRIS in a TARIS clinical study; Evidence of Hunner's Lesions on previous cystoscopy.
Start Date  
07/01/2016
IRB Number  
06-15-14B
Principal Investigator  
Kennelly, Michael
Contact Name  
Ali

For More Information, Contact   Ali  DeMarco , BS
Phone:  (704) 355-1970  Email:  ali.demarco@carolinashealthcare.org
Address:  1023 Edgehill Road
Charlotte, NC 28207
Close